The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Prognostic impact of carcinoid heart disease in SI-NET and carcinoid syndrome
Nicola Fazio, MD, PhD, Istituto Europeo di Oncologia, Milan, Italy, comments on the clinical significance and prognostic impact of carcinoid heart disease (CHD) in patients with small intestinal neuroendocrine tumors (SI-NET) and carcinoid syndrome (CS). Based on a study across two NET referral centers, CHD was present in approximately a quarter of patients. Key diagnostic markers include elevated urinary 5-hydroxyindoleacetic acid (5-HIAA) and plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, supporting early echocardiogram screening. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
